LONZA GLOBAL SHOWCASE PRESENTATION Superior T Cell Expansion Using TheraPEAK® T-VIVO®, a Chemically-defined Cell Culture Medium for Cell Therapy
Friday, June 2, 2023 01:00 PM - 01:15 PM
Global Showcase Theater
Global Showcase Presentation
Superior T Cell Expansion Using TheraPEAK® T-VIVO®, a Chemically-defined Cell Culture Medium for Cell Therapy
Presenter
Chengkang Zhang, PhD, Senior Scientist, Lonza, USA
One of the weak links in the cGMP manufacturing of T-cell therapy is the use of human serum, which may contain adventitious agents requiring stringent safety testing and factors detrimental for T cell expansion. In addition, the performance of human serum may vary considerably from lot to lot, necessitating screening and stockpiling. The supply of high-quality human serum may be insufficient to meet global demand as more blockbuster T cell therapies are approved and become one pillar for modern medicine.
We have developed TheraPEAK® T-VIVO® Cell Culture Medium, which incorporates only recombinant proteins, is free of undefined animal origin components, and requires only the addition of cytokines and activation agents, thus streamlining the CAR-T cell therapy manufacturing process. This medium supports superior T cell expansion compared to other commercial T cell expansion media which require supplementation with human serum. TheraPEAK® T-VIVO® Medium represents an important step in making T cell therapy more consistent and scalable. The absence of human serum necessitates some changes in common cell culture procedures. Alternative handling practices to be considered when using a chemically-defined medium for CAR-T cell therapies will be discussed.
Presenter
Chengkang Zhang, PhD, Senior Scientist, Lonza, USA
One of the weak links in the cGMP manufacturing of T-cell therapy is the use of human serum, which may contain adventitious agents requiring stringent safety testing and factors detrimental for T cell expansion. In addition, the performance of human serum may vary considerably from lot to lot, necessitating screening and stockpiling. The supply of high-quality human serum may be insufficient to meet global demand as more blockbuster T cell therapies are approved and become one pillar for modern medicine.
We have developed TheraPEAK® T-VIVO® Cell Culture Medium, which incorporates only recombinant proteins, is free of undefined animal origin components, and requires only the addition of cytokines and activation agents, thus streamlining the CAR-T cell therapy manufacturing process. This medium supports superior T cell expansion compared to other commercial T cell expansion media which require supplementation with human serum. TheraPEAK® T-VIVO® Medium represents an important step in making T cell therapy more consistent and scalable. The absence of human serum necessitates some changes in common cell culture procedures. Alternative handling practices to be considered when using a chemically-defined medium for CAR-T cell therapies will be discussed.
SPONSORED BY:
